Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
@vculiver.bsky.social
The Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University is revolutionizing global health through innovative liver research. 804-828-5066.
🚨NEW IN #NEJM🚨ESSENCE #VCU-led researchers report weekly injections of #semaglutide resolved steatohepatitis without worsening of fibrosis in 63% of #MASH patients getting weekly semaglutide injections, across 37 countries. #liver www.nejm.org/doi/full/10....
April 30, 2025 at 9:04 PM
🚨NEW IN #NEJM🚨ESSENCE #VCU-led researchers report weekly injections of #semaglutide resolved steatohepatitis without worsening of fibrosis in 63% of #MASH patients getting weekly semaglutide injections, across 37 countries. #liver www.nejm.org/doi/full/10....
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Screening for MASLD by at 29th Annual Virginia Liver Symposium by @juanpabloarab.bsky.social @vculiver.bsky.social
🌎 prevalence of MASLD 30%
⬆️ risk progression with DM, HTN, obesity, menopause
Screen for 🍷
♻️ Putative connection between MASLD, CVD, CKD
🌎 prevalence of MASLD 30%
⬆️ risk progression with DM, HTN, obesity, menopause
Screen for 🍷
♻️ Putative connection between MASLD, CVD, CKD
April 26, 2025 at 7:12 PM
Screening for MASLD by at 29th Annual Virginia Liver Symposium by @juanpabloarab.bsky.social @vculiver.bsky.social
🌎 prevalence of MASLD 30%
⬆️ risk progression with DM, HTN, obesity, menopause
Screen for 🍷
♻️ Putative connection between MASLD, CVD, CKD
🌎 prevalence of MASLD 30%
⬆️ risk progression with DM, HTN, obesity, menopause
Screen for 🍷
♻️ Putative connection between MASLD, CVD, CKD
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
March 2, 2025 at 5:46 PM
Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social
March 2, 2025 at 2:30 PM
Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social
Thrilled that we're represented!
Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
March 3, 2025 at 2:53 PM
Thrilled that we're represented!
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
ASCI member Jasmohan S. Bajaj @jasmohanbajaj et al. @VCU_liver show that fecal transplant ameliorates a source of cirrhosis progression:
JCI Insight - Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with FMT
Research LetterIn-Press PreviewHepatologyMicrobiology Open Access | 10.1172/jci.insight.186649
insight.jci.org
February 27, 2025 at 6:38 PM
ASCI member Jasmohan S. Bajaj @jasmohanbajaj et al. @VCU_liver show that fecal transplant ameliorates a source of cirrhosis progression:
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
Before reading this excellent perspective, I had no idea that the data supporting the use of antibiotic prophylaxis for SBP were so weak. Really time to re-think this "standard-of-care" practice!
Highly recommended. #IDSky
doi.org/10.1093/cid/...
Highly recommended. #IDSky
doi.org/10.1093/cid/...
Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: First, Do No Harm
Abstract. Antibiotic prophylaxis for spontaneous bacterial peritonitis (SBPPr) in patients with cirrhosis has been considered standard of care since the 19
doi.org
February 5, 2025 at 1:43 PM
🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
🙏 for highlighting our commentary @cidjournal.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis
➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit
doi.org/10.1093/cid/...
#IDSky
➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit
doi.org/10.1093/cid/...
#IDSky
February 3, 2025 at 3:53 PM
🙏 for highlighting our commentary @cidjournal.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Check out @nytimes.com interview of experts re: #wellness my tip? Coffee for the win!! Liver brain and microbes all benefit from this
Check it out below
www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social
Check it out below
www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social
January 13, 2025 at 4:01 PM
Check out @nytimes.com interview of experts re: #wellness my tip? Coffee for the win!! Liver brain and microbes all benefit from this
Check it out below
www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social
Check it out below
www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social
Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Gastroenterology>General Hepatology
FDA Issues Safety Alert on Liver Disease Drug.
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis.
by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...
FDA Issues Safety Alert on Liver Disease Drug.
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis.
by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...
FDA Issues Safety Alert on Liver Disease Drug
Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis
www.medpagetoday.com
December 14, 2024 at 7:37 AM
Gastroenterology>General Hepatology
FDA Issues Safety Alert on Liver Disease Drug.
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis.
by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...
FDA Issues Safety Alert on Liver Disease Drug.
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis.
by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...
Taking a first step on Bsky ... here's our team and colleagues at #VCU's Division of GI, Hep and Nutrition. #liversky #gastrosky
December 16, 2024 at 4:05 PM
Taking a first step on Bsky ... here's our team and colleagues at #VCU's Division of GI, Hep and Nutrition. #liversky #gastrosky